VIJOINT HCC

Vijoint HCC is a patented fixed combination of Hyaluronic Acid (HA) sodium salt 2%, chondroitin-Sulfate 2% (CS) and Hydroxypropyl beta-Cyclodextrin 1%. HA AND CS ACT IN SYNERGY TO CONTRAST DISEASE SYMPTOMS AND SLOW DOWN ITS PROGRESSION. YOUNG TARGETHYALURONIC ACID SYSADOA: SYMPTOMATICSLOW-ACTING DRUG: improving pain, inflammation and joint function. ELDER TARGET CHONDROITINSULFATE DMOAD. DISEASE MODIFYING OSTEOARTHRITIS DRUG: Favouring subchondral bone formationReducing the rate of decline in minimum joint space Vijoint HCC, as recommended by international Guidelines, contains pharma grade CS of marine origin (from shark) that differs for anticoagulant, anti-inflammatory and stimulating neurite outgrowth activities, from common terrestrial sources. Vijoint HCC is a 3D complex, formulated as HA functionalized with beta-cyclodextrin, a molecular basket , which hosts inside the chondroitin-sulphate and: overcomes the poor absorption (only 12-13%) of chondroitin taken orallyincreases the viscosity of hyaluronic acid and its loading in the jointprotects hyaluronic acid from the enzymatic degradation of hyaluronidasesIMPROVED RESISTANCE TO THE HYALURONIDASES Hyaluronic acid is subject to progressive degradation when in contact with hyaluronidases enzymes. Vijoint HCC, as a polymeric complex of hyaluronic acid, chondroitinsulphate and cyclodextrin, has a significantly lower enzymatic degradation rate than preparations based on hyaluronic acid only. An in vitro study showes the VIJOINT HCC better resistance to the hyaluronidases, expressed by a reduced formation of N-acetylexosamines terminals exposed by enzymatic cutting action. Vijoint HCC exhibits a relevant reduction in enzymatic degradation compared to the combination of hyaluronic acid and chondroitin sulfate and not only to the solution containing sodium hyaluronate alone.